Medwaala Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 29-12-2024
- Paid Up Capital ₹ 0.10 M
as on 29-12-2024
- Company Age 8 Year, 9 Days
- Last Filing with ROC 31 Mar 2024
- Revenue 2.08%
(FY 2020)
- Profit 102.17%
(FY 2020)
- Ebitda 93.42%
(FY 2020)
- Net Worth 0.96%
(FY 2020)
- Total Assets 13.41%
(FY 2020)
About Medwaala Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Gurpreet Kaur and Gurmeet Singh serve as directors at the Company.
- CIN/LLPIN
U33119DL2017PTC310008
- Company No.
310008
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Jan 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Medwaala Pharmaceuticals Private Limited offer?
Medwaala Pharmaceuticals Private Limited offers a wide range of products and services, including Surgical & ICU Equipments, Pulse Oximeter, Glucometer & POCT Devices, Medical Laboratory Instruments, Sugar Test Strips, Hematology Analyzers, Rapid Test Kit, Oxygen Concentrator, Corona Test Kit.
Who are the key members and board of directors at Medwaala Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gurpreet Kaur  | Director | 21-Feb-2020 | Current |
| Gurmeet Singh | Director | 02-Jan-2017 | Current |
Financial Performance of Medwaala Pharmaceuticals.
Medwaala Pharmaceuticals Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 2.08% increase. The company also saw a substantial improvement in profitability, with a 102.17% increase in profit. The company's net worth moved up by a moderate rise of 0.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medwaala Pharmaceuticals?
Unlock access to Medwaala Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Medwaala Pharmaceuticals?
Unlock and access historical data on people associated with Medwaala Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medwaala Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medwaala Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
